05 Nov 2026, 06:50 IST
Dr. Lal Path Labs Ltd.
HDFC Securities · BUY · target INR 2,330
The report notes an EBITDA beat driven by volume and realization growth and reiterates BUY with a raised target price.
From HSIE Results Daily 05 Nov 26 HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.